587 related articles for article (PubMed ID: 30449681)
41. Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma.
Sato T; Tsuchiya A; Owaki T; Kumagai M; Motegi S; Iwasawa T; Nojiri S; Ogawa M; Takeuchi S; Watanabe Y; Kawata Y; Kamimura H; Terai S
Biochem Biophys Res Commun; 2021 Aug; 566():36-44. PubMed ID: 34116355
[TBL] [Abstract][Full Text] [Related]
42. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
43. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.
Chen K; Ma J; Jia X; Ai W; Ma Z; Pan Q
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):117-125. PubMed ID: 30528647
[TBL] [Abstract][Full Text] [Related]
44. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.
Kumar DP; Santhekadur PK; Seneshaw M; Mirshahi F; Uram-Tuculescu C; Sanyal AJ
Hepatology; 2019 Apr; 69(4):1520-1534. PubMed ID: 30394550
[TBL] [Abstract][Full Text] [Related]
45. Preclinical models of non-alcoholic fatty liver disease.
Santhekadur PK; Kumar DP; Sanyal AJ
J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
[TBL] [Abstract][Full Text] [Related]
46. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
47. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice.
Iida A; Kuranuki S; Yamamoto R; Uchida M; Ohta M; Ichimura M; Tsuneyama K; Masaki T; Seike M; Nakamura T
Exp Anim; 2019 Nov; 68(4):417-428. PubMed ID: 31155606
[TBL] [Abstract][Full Text] [Related]
48. Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer.
Zhang T; Kho DH; Wang Y; Harazono Y; Nakajima K; Xie Y; Raz A
PLoS One; 2015; 10(3):e0118448. PubMed ID: 25789613
[TBL] [Abstract][Full Text] [Related]
49. [Which animal models of nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) have more practical value in experimental investigations?].
Duan NN; Wu J
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):230-3. PubMed ID: 27095770
[TBL] [Abstract][Full Text] [Related]
50. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice.
Ling C; Liu SS; Wang YY; Huo GT; Yang YW; Xu N; Wang H; Wu Y; Miao YF; Fu R; Zhao YW; Fan CF
Zool Res; 2024 May; 45(3):551-566. PubMed ID: 38757223
[TBL] [Abstract][Full Text] [Related]
52. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
Kurhe Y; Caputo M; Cansby E; Xia Y; Kumari S; Anand SK; Howell BW; Marschall HU; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2022; 13(2):405-423. PubMed ID: 34624527
[TBL] [Abstract][Full Text] [Related]
53. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma.
Muir K; Hazim A; He Y; Peyressatre M; Kim DY; Song X; Beretta L
Cancer Res; 2013 Aug; 73(15):4722-31. PubMed ID: 23749645
[TBL] [Abstract][Full Text] [Related]
54. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
55. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
56. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
Cuadrado A; Orive A; García-Suárez C; Domínguez A; Fernández-Escalante JC; Crespo J; Pons-Romero F
Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
[TBL] [Abstract][Full Text] [Related]
57. Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Hymel E; Fisher KW; Farazi PA
BMC Cancer; 2022 Dec; 22(1):1276. PubMed ID: 36474183
[TBL] [Abstract][Full Text] [Related]
58. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
[TBL] [Abstract][Full Text] [Related]
59. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
Foerster F; Gairing SJ; Müller L; Galle PR
J Hepatol; 2022 Feb; 76(2):446-457. PubMed ID: 34555422
[TBL] [Abstract][Full Text] [Related]
60. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.
Lequoy M; Gigante E; Couty JP; Desbois-Mouthon C
Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32112699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
